$TNXP News

Tonix Secures Medicare Coverage For Fibromyalgia Drug TONMYA, Expands TONMYA Coverage To 145M Lives By 2027

Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26

Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA

Tonix Pharmaceuticals Enters Agreement With A Group Purchasing Organization To Provide Coverage For TONMYA To An Additional ~17M U.S. Commercial Lives From June 1

Tonix Pharma Presents Data From Real-World Claims Analysis Of Opioid Use In US Adults With Fibromyalgia At 2026 ASCP Annual Meeting

Tonix Pharmaceuticals' TNX-1500 Shows Favorable Safety Profile In Phase 1 Study As Phase 2 Kidney Transplant Trial Set For 2nd Half 2026

Tonix Pharmaceuticals' ISPOR 2026 Data Show 93.2% Comorbidity Burden And $29,896 Annual Inpatient Costs Among Fibromyalgia Patients

Tonix Pharmaceuticals (NASDAQ:TNXP) Beats Revenue Estimates in First Full Quarter of TONMYA Sales

Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate

Why Tonix Pharmaceuticals Shares Are Rallying Wednesday

Tonix Pharmaceuticals Announced An Agreement Effective May 1, 2026, With Group Purchasing Organization For Tonmya (Cyclobenzaprine HCL Sublingual Tablets)

TD Cowen Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $22

Tonix Pharma Presents Phase 1 Data And Plans For Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease In US At 4th Annual Ticks And Tickborne Diseases Symposium

Tonix Pharma Announces Oral Presentation And Two Poster Presentations On Preclinical Immuno-Oncology Portfolio At AACR Annual Meeting 2026

Tonix Pharmaceuticals Announces Publication Of The Paper "Steady-State Pharmacokinetic Properties Of TNX-102 SL, A Sublingual Tablet Formulation Of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing In Healthy Volunteers: A Randomized, Open-label Trial," In The Journal 'Clinical Pharmacology In Drug Development'

Tonix Pharmaceuticals Says Phase 1 Data of TNX-4800 (mAb 2217LS) For Preventing Lyme Disease Demonstrated Safety, Tolerability, And Pharmacokinetics Supportive Of Approximately Four Months Protection

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Tonix Announces First Participant Dosed In Phase 1 Investigator-Initiated Study To Evaluate Effect Of TNX-1900 On Trigeminal Nerve-Mediated Vasodilation Of Forehead Using Capsaicin As Well As Electrical Stimulation